Farallon Capital Management’s Fate Therapeutics FATE Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,900	Closed	-$1.24M	–	320
2022 Q1	$1.24M	Sell	31,900 -725,525	-96%	-$28.1M	0.01%	216
2021 Q4	$44.3M	Sell	757,425 -1,553,973	-67%	-$88.1M	0.25%	71
2021 Q3	$137M	Buy	2,311,398 +406,398	+21%	+$31.9M	0.74%	44
2021 Q2	$165M	Buy	1,905,000 +5,000	+0.3%	+$403K	0.8%	39
2021 Q1	$157M	Sell	1,900,000 -1,100,000	-37%	-$105M	0.81%	37
2020 Q4	$273M	Sell	3,000,000 -125,000	-4%	-$7.76M	1.69%	26
2020 Q3	$125M	Sell	3,125,000 -375,000	-11%	-$13.1M	0.89%	41
2020 Q2	$120M	Buy	3,500,000 +500,000	+17%	+$14.9M	0.96%	36
2020 Q1	$66.6M	Buy	3,000,000 +750,000	+33%	+$19M	0.61%	35
2019 Q4	$44M	Hold	2,250,000	–	–	0.34%	60
2019 Q3	$34.9M	Sell	2,250,000 -250,000	-10%	-$4.79M	0.29%	57
2019 Q2	$50.8M	Hold	2,500,000	–	–	0.35%	56
2019 Q1	$43.9M	Buy	2,500,000 +300,000	+14%	+$4.74M	0.36%	56
2018 Q4	$28.2M	Buy	2,200,000 +1,670,000	+315%	+$23.3M	0.25%	61
2018 Q3	$8.63M	Buy	+530,000	New	+$6.27M	0.06%	86
2014 Q4	–	Sell	-171,196	Closed	-$880K	–	93
2014 Q3	$880K	Sell	171,196 -76,906	-31%	-$445K	0.01%	82
2014 Q2	$1.57M	Sell	248,102 -26,898	-10%	-$189K	0.02%	90
2014 Q1	$2.68M	Sell	275,000 -269,243	-49%	-$2.08M	0.05%	70
2013 Q4	$3.42M	Buy	+544,243	New	+$3.43M	0.07%	70

Other funds holding FATE